Hillstar Bio Secures $67 Mn Series A to Advance Autoimmune & Arthritis Treatments
The funding will support Hillstar Bio’s lead program targeting TRBV9+ T cells, which is scheduled for clinical trials in 2026.
Hillstar Bio, a new player in the American biotech market, has announced the closing of a $67 million Series A financing round.
The Boston-based company specializes in precision immunology therapies for autoimmune diseases.
Prominent investors and shareholders led the funding from the US, Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience.
The funding will support Hillstar Bio’s lead program targeting TRBV9+ T cells, which is scheduled for clinical trials in 2026. This program focuses on axial spondyloarthritis (AxSpA) and other immune conditions associated with HLA-B27.
Additionally, the investment will help expand Hillstar Bio’s pipeline of precision immunology therapies targeting specific immune cell subsets across various autoimmune diseases.
The leadership team includes Robert Mabry, Ph.D., as CEO; Mitchell Keegan, Ph.D., as Chief Development Officer; and Lauren Mifflin, Ph.D., MBA, as COO. The board of directors features experts such as Luc Dochez, Dan Estes, and Kenneth Harrison.
Hillstar Bio is a biotechnology company headquartered in Boston, Massachusetts, specializing in precision immunology therapies for autoimmune diseases.
Founded in 2023, the company is focused on developing next-generation treatments that selectively target and deplete pathogenic immune cells while preserving healthy ones. The company’s approach targets disease mechanisms directly, minimizing risks associated with prolonged immune suppression.
